Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Li... ( CAMBRIDGE Mass. Feb. 25 /- Idenix...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)

Date:2/25/2008

CAMBRIDGE, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, announced today that three abstracts have been accepted for presentation at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, April 23 - 27, 2008. Full abstracts can now be viewed at the EASL website at http://www.easl.ch.

David Standring, Ph.D., Executive Vice President, Biology at Idenix Pharmaceuticals, will present "In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors" in an oral presentation session at 6:15 p.m. CET on Thursday, April 24, 2008.

Dr. Standring will also present, "Potent Antiviral Activity of Second Generation Nucleoside Inhibitors, IDX102 and IDX184, in HCV-Infected Chimpanzees" in an oral presentation session at 5:30 p.m. CET on Friday, April 25, 2008.

Erika Cretton-Scott, Ph.D., Director, Preclinical Pharmacology at Idenix Pharmaceuticals, will present "In Vitro Antiviral Activity and Pharmacology of IDX184, a Novel and Potent Inhibitor of HCV Replication" in a poster session beginning on Thursday, April 24, 2008.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

Post Your Comments:

(Date:11/30/2009)...G OF PRUSSIA, Pa., Nov. 30 Cadien...zing in interactive marketing services and soluti...he launch of its HATCH Consulting services g...ng strategic experts across a range of emerging ar...nsulting team is committed to guiding companies an...

(Date:11/30/2009)...CLIFF MANOR, N.Y., Nov. 30 Good Pu...nt for the publication of company-sponsored medica... British Medical Journal (BMJ). "The publication o...nce of providing support and guidance for industry...esults in the peer-reviewed medical literature," s...

(Date:11/30/2009)... Md., Nov. 30 Novavax, I...ted enrollment in the Phase II clinical study of i...nded strains) VLP vaccine candidate in healthy adu... randomized, double-blind, active-controlled study...enicity of two different doses (15 mcg and 60 mcg)...

(Date:11/30/2009)...d COPENHAGEN, Nov. 30 Exiqon A/S (... the Harvard Medical School ICCB-Longwood Screenin...RNA Screening Center of Excellence. ICCB-L suppor...sociated hospitals and institutions, for high-thro...ies. ,, MicroRNAs are a novel class of small, n...

Breaking Biology Technology:Cadient Interactive Announces the Launch of HATCH Consulting Services 2 Cadient Interactive Announces the Launch of HATCH Consulting Services 3 ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2 ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3 NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4 Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2 Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3

[0] Cadient Interactive Announces the Launch of HATCH Consulting Services [1] ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ [0] NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults [0] Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence

...edical,Technologies, Inc. (Nasdaq: VNUS ), a lead...invasive treatment of peripheral vascular disease,...ial results for the third,quarter ended September ..., VNUS plans to host its regular quarterly teleco... 29. This call will be webcast live for all,invest...

..., NAPA, Calif., Oct. 13 Senetek PLC (OTC,Bulleti...n the development,of technologies that target the ... company continues to maintain a strong, debt-free...excess of $16 Million; $10 Million,of which is inv...eposits,and $6 Million on deposit in a money marke...

...USSELS, October 13 The International Diabetes,Fed...together key opinion,leaders to push for action to...abetes in developing countries without access to c...edicines for Children in the,Developing World, wil...d,Kingdom. The International Diabetes Federation h...

Other Biology Technology:VNUS Medical Technologies to Report Third-Quarter 2008 Results and Webcast Teleconference on October 29 2 Senetek Affirms Strong Financial Position 2 Senetek Affirms Strong Financial Position 3 International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 2 International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 3

VNUS Medical Technologies to Report Third-Quarter 2008 Results and Webcast Teleconference on October 29 Senetek Affirms Strong Financial Position International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive

(Date:11/26/2009)...ried out in eight European countries has shown tha...sease pandemic could have a significant role in re...n the open access journal BMC Infectious Diseases...ays and weekends/holidays, finding that they were ... Hasselt and Antwerp University, Belgium, led a te...

(Date:11/26/2009)...illin-resistant Staphylococcus Aureus ) and other...s low-temperature plasma prototype devices have be...ing bactericidal cocktails. , Two prototype devi...ction of healthy skin (e.g. hands and feet) in hos... lethal threat; and another to shoot bacteria-kill...

(Date:11/25/2009)... Bacteria don,t have easy lives. In addition to ma... have natural enemies called bacteriophages, virus...days. , Still, bacteria and another class of mi...xtreme environments such as deep-sea volcanic vent...ey have a built-in defense system that helps prote...

[0] School closure could reduce swine flu transmission by 21 percent [0] Plasma produces KO cocktail for MRSA [1] Researchers discover biological basis of 'bacterial immune system'

...onal Institute of Allergy and Infectious Diseases ... Health, have discovered a survival mechanism in a...he mechanism lets the bacteria protect itself by w...Ps), which are defense molecules sent by the body ...types, gram-positive and gram-negative, with the p...

...ain different gene mutations, but just how these m...been a mystery. , A new clue comes from scientists...l Schools of Medicine and Public Health. Their res... birth to 20 years old, may specifically increase ...different mutation, on the NRAS gene, was found in...

... shown a significant increase in Northern Ireland ...t men, older people and those living in more afflu...the June issue of British Journal of Dermatology. ...tics for nearly 23,000 patients over a 12-year per...nd a 62 per cent increase in skin cancer samples p...

Other Biology News:Newly found sensing system enables certain bacteria to resist human immune defenses 2 Sun exposure early in life linked to specific skin cancer gene mutation 2 Rising skin cancer rates are more likely to affect wealthy people, says 12-year review 2 Rising skin cancer rates are more likely to affect wealthy people, says 12-year review 3

Newly found sensing system enables certain bacteria to resist human immune defenses Sun exposure early in life linked to specific skin cancer gene mutation Rising skin cancer rates are more likely to affect wealthy people, says 12-year review

Goat Anti-Zebrafish Ephrin-B2 Polyclonal Antibody, Biotin Conjugated from R&D Systems

PhotoMan Direct Copy Hood and UV Shield set, 10 x 12 cm from Hoefer, Inc.

Donor Goat Serum from Lifeblood Medical, Inc.

GeneRacer Kit with SuperScript II RT and Zero Blunt TOPO PCR Cloning kit for Sequencing from Invitrogen

Biology Products:

Goat Anti-Zebrafish Ephrin-B2 Polyclonal Antibody, Biotin Conjugated from R&D Systems PhotoMan Direct Copy Hood and UV Shield set, 10 x 12 cm from Hoefer, Inc.Donor Goat Serum from Lifeblood Medical, Inc.GeneRacer Kit with SuperScript II RT and Zero Blunt TOPO PCR Cloning kit for Sequencing from Invitrogen

Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Li...( CAMBRIDGE Mass. Feb. 25 /- Idenix...)